- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL
April 4th 2016, 9:57am
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).
NCCN Refines Recommendations for Breast Cancer Care
April 2nd 2016, 4:12pm
At the 2016 NCCN Annual Conference, William J. Gradishar, MD, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.
TKIs Dominate NCCN Update in EGFR+ NSCLC
April 2nd 2016, 3:16pm
Testing for EGFR mutations should be routine in patients with non–small cell lung cancer. With the presence of an EGFR mutation TKIs are an appropriate treatment option across multiple lines of therapy, according to the latest update from the NCCN.
Optimizing Current Treatments for CLL as New Agents Are Investigated
April 2nd 2016, 1:52pm
Jeffrey Jones, MD, updated attendees at the 2016 NCCN Annual Conference on the latest developments in chronic lymphocytic leukemia.
NCCN Broadens Myeloma Diagnostic Criteria, Recommends Novel Agents
April 2nd 2016, 1:24pm
The updated NCCN myeloma guideline broadens the diagnostic criteria for active disease and integrates novel therapies into the treatment paradigm.
Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines
April 2nd 2016, 11:05am
Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.
Dr. Anderson on How the Definition of Myeloma Has Changed
April 2nd 2016, 5:08am
Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how the definition of myeloma has changed.
NCCN Readies Practitioners for Tapping the Potential of Biosimilars
April 1st 2016, 2:38pm
While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.
Dr. Salerno Discusses Hypofractionation for Early Breast Cancer
April 1st 2016, 11:18am
Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.
NCCN Guideline Expands Locoregional Treatment Candidates in HCC
April 1st 2016, 8:36am
Locoregional therapies are now considered potentially curable options that should be considered alongside transplant and resection for patients with hepatocellular carcinoma.
Dr. Mohler on Overuse of ADT in Prostate Cancer and NCCN Guidelines
April 1st 2016, 8:06am
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses the use of androgen-deprivation therapy (ADT) for patients with prostate cancer and how the use is reflected in the NCCN guidelines.
NCCN's Evidence Blocks Make the Best of Imprecise Drug Data
March 31st 2016, 3:13pm
The NCCN's Evidence Blocks need further data and refinement to overcome subtleties of distinction in drug performance, but they’re the best value system developed so far, NCCN officials reported at their 2016 Annual Conference.
Dr. Zelenetz on the Role of Biosimilars in Cancer Care
March 31st 2016, 2:06pm
Andrew D. Zelenetz, MD, PhD, medical director, Quality Informatics, Memorial Sloan Kettering Cancer Center, discusses the role of biosimilars in cancer care. Zelenetz spoke about this topic at the 2016 NCCN Annual Conference.
Dr. Covey on Recent and Future Changes to the NCCN Guidelines for HCC
March 31st 2016, 1:14pm
Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses recent and future changes to locoregional treatment approaches for hepatocellular carcinoma (HCC).
The Many Facets of Palliative Care Call for Team-Based Approach
March 31st 2016, 1:02pm
The 2016 NCCN Annual Conference included a push to find more effective ways to encourage and deliver palliative care services across a variety of settings in oncology.
“Forgotten Lessons” May Help Advance Colorectal Cancer Care
March 31st 2016, 12:00pm
Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.
Targeted Drug Falls Short Versus Paclitaxel for Ovarian Cancer
March 22nd 2016, 1:02pm
Weekly paclitaxel for recurrent ovarian cancer prevailed over the VEGF inhibitor cabozantinib in a randomized comparison of the two drugs.
Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity
March 22nd 2016, 12:42pm
Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.
Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval
March 22nd 2016, 10:46am
Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.
Dr. Jean Hurteau on Diagnosing Ovarian Clear Cell Carcinoma
March 21st 2016, 2:23pm
Jean Hurteau, MD, professor, Division of Gynecologic Oncology at NorthShore University Health System, discusses the difficulties of diagnosing ovarian clear cell carcinoma. Hurteau says data for the diagnosis of the carcinoma is older, and is not relevant to contemporary diagnoses due to the fact that there were more mixed tumors previously than there are now.